EXELIXIS, INC.EXELEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 11.60% | 36.0M | — | 2024-01-24 |
| The Vanguard Group | 10.18% | 31.7M | — | 2024-02-13 |
| NOS. OF ABOVE PERSONS | 5.16% | 15.6M | — | 2024-02-13 |
| Farallon Capital Partners, L.P. | 0.80% | 2.2M | ▲ +0.10pp | 2024-05-08 |
| Caligan Partners LP | 0.28% | 910.7K | — | 2023-06-02 |
Insider Transactions
Net 90d: −$20.60M · buys $0 / sells $20.60MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-26 | Dana Aftab | EVP, Research and Development | Grant | 52.0K | $0.00 | $0 |
| 2026-02-26 | Brenda Hefti | SVP and General Counsel | Grant | 23.1K | $0.00 | $0 |
| 2026-02-26 | MORRISSEY MICHAEL | President and CEO | Grant | 160.4K | $0.00 | $0 |
| 2026-02-26 | Senner Christopher J. | EVP and CFO | Grant | 52.0K | $0.00 | $0 |
| 2026-02-26 | Haley Patrick J. | EVP, Commercial | Grant | 40.5K | $0.00 | $0 |
| 2026-02-24 | MORRISSEY MICHAEL | President and CEO | Gift | 100.3K | $0.00 | $0 |
| 2026-02-24 | Dana Aftab | EVP, Research and Development | Sell (open market) | 47.9K | $44.50 | $2.13M |
| 2026-02-19 | Dana Aftab | EVP, Research and Development | Sell (open market) | 29.9K | $44.35 | $1.32M |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Option exercise | 20.6K | $19.77 | $407.9K |
| 2026-02-18 | WYSZOMIERSKI JACK L | Director | Sell (open market) | 99.6K | $44.01 | $4.38M |
1–10 of 30
Page 1 / 3